广泛期小细胞肺癌BRCA2基因突变状态与一线化疗疾病无进展生存期的相关性分析  

Relationship between BRCA2 Gene Mutation Status and Progression Free Survival of First-line Chemotherapy in Extensive Small Cell Lung Cancer Based on NGS Technology

作　　者：杨盛 刘鑫 邢亚桓 YANG Sheng;LIU Xin;XING Yahuan(Xuchang Central Hospital Affiliated to Henan University of Science and Technology,Xuchang,461000)

机构地区：[1]河南科技大学附属许昌市中心医院,461000

出　　处：《实用癌症杂志》2023年第2期274-277,共4页The Practical Journal of Cancer

摘　　要：目的探讨广泛期小细胞肺癌BRCA2基因突变状态与一线化疗疾病无进展生存期(PFS)的相关性。方法选择89例广泛期小细胞肺癌患者,对其实施一线化疗方案;应用NGS技术检测患者血液BRCA2基因突变状态。对患者进行随访,记录PFS,采用Cox模型分析BRCA2基因突变与PFS相关性。结果经NGS技术检测,BRCA2基因突变12例,突变率为13.48%。不同性别、年龄、吸烟史患者的BRCA2基因突变率差异无统计学意义(P>0.05),周围型患者BRCA2基因突变率高于中央型(P<0.05)。患者化疗后PR14例、SD47例、PD28例;随访结果显示,患者中位PFS为4.8个月。单因素显示,患者性别、年龄、有无吸烟、解剖类型对其PFS无显著影响(P>0.05),病情有无控制、BRCA2基因是否突变对PFS有显著影响(P<0.05)。经Cox回归分析显示,一线化疗疗效、BRCA2基因突变状态是患者化疗PFS的独立危险因素(P<0.05)。结论广泛期小细胞肺癌患者的BRCA2基因突变状态与一线化疗疾病PFS密切相关,临床可应用NGS技术检测基因突变状态评估患者疗效及预后。Objective To investigate the relationship between BRCA2 gene mutation status and progression free survival(PFS)of first-line chemotherapy in extensive small cell lung cancer based on second-generation sequencing(NGS).Methods 89 patients with extensive small cell lung cancer were treated with first-line chemotherapy;NGS technique was used to detect the mutation status of BRCA2 gene in patients’blood.The patients were followed up,PFS was recorded,and the correlation between BRCA2 gene mutation and PFS was analyzed by Cox model.Results The number of BRCA2 gene mutations was 12,and the mutation rate was 13.48%.There was no significant difference in BRCA2 gene mutation rate in gender,age and smoking history(P>0.05).The BRCA2 gene mutation rate in peripheral type patients was higher than that in central type(P<0.05).After chemotherapy,there were 14 cases of PR,47 cases of SD and 28 cases of PD;The follow-up results showed that the median PFS was 4.8 months.Single factor showed that gender,age,smoking and anatomical type had no significant effect on PFS(P>0.05),and whether the disease was controlled and whether BRCA2 gene mutation had significant effect on PFS(P<0.05).Cox regression analysis showed that the efficacy of first-line chemotherapy and BRCA2 gene mutation were independent risk factors for chemotherapy PFS(P<0.05).Conclusion The mutation status of BRCA2 gene in patients with extensive small cell lung cancer is closely related to the first-line chemotherapy disease PFS.The gene mutation status can be detected by NGS technology to evaluate the curative effect and prognosis.

关 键 词：广泛期小细胞肺癌 二代测序 BRCA2基因突变 一线化疗 无进展生存期 

分 类 号：R734.2[医药卫生—肿瘤]